Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Astrazeneca (AZNCF) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Astrazeneca (AZNCF) over the last 16 years, with Q4 2025 value amounting to 0.09%.

  • Astrazeneca's Return on Capital Employed rose 200.0% to 0.09% in Q4 2025 from the same period last year, while for Dec 2025 it was 0.09%, marking a year-over-year increase of 200.0%. This contributed to the annual value of 0.1% for FY2025, which is 200.0% up from last year.
  • Per Astrazeneca's latest filing, its Return on Capital Employed stood at 0.09% for Q4 2025, which was up 200.0% from 0.09% recorded in Q3 2025.
  • Astrazeneca's 5-year Return on Capital Employed high stood at 0.12% for Q4 2023, and its period low was 0.0% during Q2 2022.
  • Over the past 5 years, Astrazeneca's median Return on Capital Employed value was 0.06% (recorded in 2021), while the average stood at 0.06%.
  • As far as peak fluctuations go, Astrazeneca's Return on Capital Employed plummeted by -600bps in 2022, and later surged by 700bps in 2023.
  • Astrazeneca's Return on Capital Employed (Quarter) stood at 0.03% in 2021, then surged by 60bps to 0.05% in 2022, then skyrocketed by 121bps to 0.12% in 2023, then tumbled by -37bps to 0.08% in 2024, then rose by 25bps to 0.09% in 2025.
  • Its Return on Capital Employed was 0.09% in Q4 2025, compared to 0.09% in Q3 2025 and 0.08% in Q2 2025.